Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes

European Journal of Clinical Pharmacology

Volumn 65, Issue 6, 2009, Pages 601-608

  Yang, Li Jun ^a,b   Fan, Lan ^a   Liu, Zhao Qian ^a   Mao, Yan Mei ^a   Guo, Dong ^a   Liu, Li Hui ^a   Tan, Zhi Rong ^a   Peng, Liang ^a   Han, Chun Ting ^a   Hu, Dong Li ^a   Wang, Dan ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Hunan Province People's Hospital   (China)

Author keywords

Allicin; CYP2C19; CYP3A4; Genotype; Omeprazole; Pharmacokinetics

Indexed keywords

ALLICIN; ANTIULCER AGENT; CYP2C19 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; OMEPRAZOLE; PLACEBO; SULFINIC ACID DERIVATIVE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; GENETICS; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; METABOLISM; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; ULTRAVIOLET SPECTROPHOTOMETRY;

ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; GENOTYPE; HUMANS; MALE; OMEPRAZOLE; PLACEBOS; REFERENCE VALUES; SPECTROPHOTOMETRY, ULTRAVIOLET; SULFINIC ACIDS;

EID: 68849086426     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-008-0608-1     Document Type: Article

References (42)

1. Artz MB, Harnack LJ, Duval SJ, Armstrong C, Arnett DK, Luepker RV (2006) Use of nonprescription medications for perceived cardiovascular health. Am J Prev Med 30(1):78-81 (Pubitemid 43083549)
2. Bent S, Ko R (2004) Commonly used herbal medicines in the United States: a review. Am J Med 116:478-485 (Pubitemid 38388618)
3. Blumenthal M (2003) Herbs continue slide in mainstream market: sales down 14 percent. Herbal Gram 58:71
4. Harris JC, Cottrell SL, Plummer S, Lloyd D (2001) Antimicrobial properties of Allium sativum(garlic). Appl Microbiol Biotechnol 57(3):282-286
5. Sparreboom A, Cox MC, Acharya MR, Figg WD (2004) Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22(12):2489-2503 (Pubitemid 41115408)
6. Gorinstein S, Leontowicz H, Leontowicz M, Drzewiecki J, Najman K, Katrich E (2006) Raw and boiled garlic enhances plasma antioxidant activity and improves plasma lipid metabolism in cholesterol-fed rats. Life Sci 78:655-663 (Pubitemid 41785773)
7. Durak I, Aytaç B, Atmaca Y, Devrim E, Avci A, Erol C (2004) Effects of garlic extract consumption on plasma and erythrocyte antioxidant parameters in atherosclerotic patients. Life Sci 75:1959-1966 (Pubitemid 39092560)
8. Durak I, Kavutcu M, Aytaç B, Avci A, Devrim E, Ozbek H (2004) Effects of garlic extract consumption on blood lipid and oxidant/antioxidant parameters in humans with high blood cholesterol. J Nutr Biochem 15(6):373-377 (Pubitemid 38639869)
9. Cañizares P, Gracia I, Gómez LA, Martín de Argila C, Boixeda D, García A (2004) Allyl-thiosulfinates, the bacteriostatic compounds of garlic against Helicobacter pylori. Biotechnol Prog 20(1):397-401
10. Sivam GP (2001) Protection against Helicobacter pylori and other bacterial infections by garlic. J Nutr 131:1106-1108
11. Zou L, Harkey MR, Henderson GL (2002) Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 71(13):1579-1589 (Pubitemid 34808718)
12. Foster BC, Foster MS, Vandenhoek S, Krantis A, Budzinski JW, Arnason JT (2001) An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 4(2):176-184 (Pubitemid 34305609)
13. Markowitz JS, Devane CL, Chavin KD, Taylor RM, Ruan Y, Donovan JL (2003) Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther 74(2):170-177 (Pubitemid 36951814)
14. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y (2002) Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 72(3):276-287
15. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. J Bio Chem 269:15419-15422
16. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin in Japanese. Mol Pharmacol 46:594-598 (Pubitemid 24334747)
17. Brosen K, de Morais SM, Meyer UA, Goldstein JA (1995) A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 5:312-317
18. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T (1993) Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 266:52-59 (Pubitemid 23315627)
19. Karam WG, Goldstein JA, Lasker JM, Ghanayem BI (1996) Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos 24:1081-1087 (Pubitemid 26346220)
20. Chang M, Tybring G, Dahl ML, Götharson E, Sagar M, Seensalu R (1995) Interphenotype differences in disposition and effect on gastrin levels of omeprazole -suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 39:511-518
21. Böttiger Y, Tybring G, Götharson E, Bertilsson L (1997) Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 62:384-391 (Pubitemid 27475222)
22. Tassaneeyakul W, Vannaprasaht S, Yamazoe Y (2000) Formation of omeprazole sulfone but not 5-hydroxyomeprazole is inhibited by grapefruit juice. Br J Clin Pharmacol 49:139-144 (Pubitemid 30068291)
23. Shu Y, Wang LS, Xiao WM, Wang W, Huang SL, Zhou HH (2000) Probing CYP2C19 and CYP3A4 activities in Chinese liver microsomes by quantification of 5-hydroxyomeprazole and omeprazole sulfone. Acta Pharmacologica Sinica 21:753-758 (Pubitemid 30626469)
24. González HM, Romero EM, Chavez T de J, Peregrina AA, Quezada V, Hoyo-Vadillo C (2002) Phenotype of CYP2C19 and CYP3A4 by determination of omeprazole and its two main metabolites in plasma using liquid chromatography with liquid-liquid extraction. J Chromatogr B Analyt Technol Biomed Life Sci 25:459-465 (Pubitemid 35223584)
25. Yin OQ, Tomlinson B, Chow AH, Waye MM, Chow MS (2004) Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability. J Clin Pharmacol 44(6):582-589 (Pubitemid 38668020)
26. Qiao HL, Hu YR, Tian X, Jia LJ, Gao N, Zhang LR (2006) Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. Eur J Clin Pharmacol 62(2):107-112
27. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T (2005) Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 20(3):153-167
28. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T (1998) Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 129(12):1027-1030 (Pubitemid 29005826)
29. Tanigawara Y, Aoyama N, Kita T, Shirakawa K, Komada F, Kasuga M (1999) CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 66:528-534
30. Roh HK, Kim PS, Lee DH, Tybring G, Sagar M, Park CS (2004) Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes. Basic Clin Pharmacol Toxicol 95(3):112-119 (Pubitemid 39331303)
31. Yasui-Furukori N, Takahata T, Nakagami T, Yoshiya G, Inoue Y, Kaneko S (2004) Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol 57(4):487-494 (Pubitemid 38519654)
32. Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Zhou HH (2004) St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 75(3):191-197 (Pubitemid 38314868)
33. Yin OQ, Tomlinson B, Waye MM, Chow AH, Chow MS (2004) Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 14(12):841-850 (Pubitemid 40054339)
34. Cho JY, Yu KS, Jang IJ, Yang BH, Shin SG, Yim DS (2002) Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Br J Clin Pharmacol 53:393-397
35. He N, Huang SL, Zhu RH, Tan ZR, Liu J, Zhu B (2003) Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent. Xenobiotica 33:211-221 (Pubitemid 36237942)
36. Li XQ, Weidolf L, Simonsson R, Andersson TB (2005) Enantiomer/enantiomer interactions between the S- and R-isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4. J Pharmacol Exp Ther 315(2):777-787 (Pubitemid 41500744)
37. Abelö A, Andersson TB, Antonsson M, Naudot AK, Skånberg I, Weidolf L (2000) Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 28(8):966-972 (Pubitemid 30612617)
38. Teyssier C, Guenot L, Suschetet M, Siess MH (1999) Metabolism of diallyl disulfide by human liver microsomal cytochromes P-450 and flavin-containing monooxygenases. Drug Metab Dispos 27(7):835-841 (Pubitemid 29297783)
39. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF (2001) Interaction of omeprazole, lansoprazole and pantoprazole with P-glyprotein. Naunyn Schmiedebergs Arch Pharmacol 364:551-557 (Pubitemid 33145095)
40. Arora A, Seth K, Shukla Y (2004) Reversal of p-glycoprotein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver. Carcinogenesis 25(6):941-949 (Pubitemid 38886080)
41. de Morais SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H (1995) Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 58:404-411
42. Jonkers D, van den Broek E, van Dooren I, Thijs C, Dorant E, Hageman G (1999) Antibacterial effect of garlic and omeprazole on Helicobacter pylori. J Antimicrob Chemother 43:837-839 (Pubitemid 29273736)